CLAIMS

1) A stable pharmaceutical solid or semisolid dispersion comprising at least one oxidation-susceptible and poorly water-soluble drug as active ingredient, a hydrophilic carrier, a water-soluble vitamin E derivative as antioxidant agent and optionally other excipients.

2) A stable pharmaceutical solid or semisolid dispersion according to claim 1 wherein the active ingredient incorporates at least one amine, aldheyde or hydroxy functional group or has at least a double or triple bond in their chemical structure and has an intrinsic solubility in water of less than about 500 ⊄g/mL.

3) A stable pharmaceutical solid or semisolid dispersion according to claim 2 wherein the active ingredient has an intrinsic solubility of less than about 200 ⊄g/mL.

4) A stable pharmaceutical solid or semisolid dispersion according to claim 1 wherein the active ingredient is seleceted from the group consisting of posaconazole, tocoretinate, nitrendipine, tiagabine, hydrocortisone/cortisol, tacrolimus, testosterone, metaclazepam, morphine, metamethasone valerate, captopril, nicotine, dronabinol, formestane, atamestane and exemestane.

5) A stable pharmaceutical solid or semisolid dispersion according to claim 1 wherein the active ingredient is exemestane.

6) A stable pharmaceutical solid or semisolid dispersion according to claim 1 wherein the amount of active ingredient is in the range of from about 25% to 1%.

7) A stable pharmaceutical solid or semisolid dispersion according to claim 6 wherein the amount of active ingredient is from 15% to 2%.

8) A stable pharmaceutical solid or semisolid dispersion according to claim 1 wherein the antioxidant agent is d-alpha-tocopherol polyethylene glycol ester.

9) A stable pharmaceutical solid or semisolid dispersion according to claim 8 wherein the oxidant agent is d-alpha-tocopherol polyethylene glycol 1000 succinate.

10) A stable pharmaceutical solid or semisolid dispersion according to claim 1 wherein the antioxidant agent is used in the range from 1% to 0.01% w/w.

11) A stable pharmaceutical solid or semisolid dispersion according to claim 1 wherein the antioxidant agent is used in the range from 0.5% to 0.02% w/w.

12) A stable pharmaceutical solid or semisolid dispersion according to claim 1 wherein the hydrophilic carrier is in an amount from 20% to 95% w/w

13) A stable pharmaceutical solid or semisolid dispersion according to claim 12 wherein the hydrophilic carrier is in an amount from 90% to 70% w/w.

14) A method of inhibiting oxidative degradation of pharmaceutical formulations containing at least one oxidation-susceptible and poorly water-soluble drug as active ingredient which method comprises adding to the formulation a low amount of a water soluble vitamin E derivative as antioxidant agent.

15) A process for preparing a stable solid or semisolid dispersion for oral administration of an oxidation -susceptible and poorly water-soluble drug which process comprises mixing the oxidation-susceptible and poorly water-soluble drug, the hydrophilic carrier and the water soluble vitamin E derivative, and melting the resultant mixture.